Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Mar 17

PMID 35296094

Authors

Xiufang Ren

Songyi Guo

Xiaojiao Guan

Ye Kang

Jiamei Liu

Xianghong Yang

Affiliations

Soon will be listed here.

Abstract

Immunity is an important physiological function acquired throughout evolution as a defense system against the invasion of pathogenic microorganisms. The immune system also eliminates senescent cells and maintains homeostasis, monitoring cell mutations and preventing tumor development the action of the immune cells and molecules. Immunotherapy often relies on the interaction of immune cells with the tumor microenvironment (TME). Based on the distribution of the number of lymphocytes (CD3 and CD8) in the center and edge of the tumor and the expression level of B7-H1/PD-L1, tumors are divided into hot tumors, cold tumors, and intermediate tumors (including immune-suppressed and isolated). This review focuses on the advances in precision combination immunotherapy, which has been widely explored in recent years, and its application in different tumor types.

Citing Articles

Integrative analysis of a novel immunogenic PANoptosis‑related gene signature in diffuse large B-cell lymphoma for prognostication and therapeutic decision-making.

Xu M, Ruan M, Zhu W, Xu J, Lin L, Li W Sci Rep. 2024; 14(1):30370.

PMID: 39639038 PMC: 11621545. DOI: 10.1038/s41598-024-81420-z.

Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC).

Mousa A, Enk A, Hassel J, Reschke R Cells. 2024; 13(19.

PMID: 39404378 PMC: 11475876. DOI: 10.3390/cells13191615.

Improving tumor microenvironment assessment in chip systems through next-generation technology integration.

Gaebler D, Hachey S, Hughes C Front Bioeng Biotechnol. 2024; 12:1462293.

PMID: 39386043 PMC: 11461320. DOI: 10.3389/fbioe.2024.1462293.

Immune effects of α and β radionuclides in metastatic prostate cancer.

Lunj S, Smith T, Reeves K, Currell F, Honeychurch J, Hoskin P Nat Rev Urol. 2024; 21(11):651-661.

PMID: 39192074 DOI: 10.1038/s41585-024-00924-5.

Microphysiological systems as models for immunologically 'cold' tumors.

Gaebler D, Hachey S, Hughes C Front Cell Dev Biol. 2024; 12:1389012.

PMID: 38711620 PMC: 11070549. DOI: 10.3389/fcell.2024.1389012.

References

Ricciuti B, Leonardi G, Puccetti P, Fallarino F, Bianconi V, Sahebkar A . Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. Pharmacol Ther. 2018; 196:105-116. DOI: 10.1016/j.pharmthera.2018.12.004. View

Kroemer G, Galluzzi L, Kepp O, Zitvogel L . Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2012; 31:51-72. DOI: 10.1146/annurev-immunol-032712-100008. View

Brenner C, Galluzzi L, Kepp O, Kroemer G . Decoding cell death signals in liver inflammation. J Hepatol. 2013; 59(3):583-94. DOI: 10.1016/j.jhep.2013.03.033. View

Yi L, Fan J, Qian R, Luo P, Zhang J . Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. Int J Cancer. 2019; 145(1):284-294. PMC: 6590181. DOI: 10.1002/ijc.32097. View

Ghislat G, Cheema A, Baudoin E, Verthuy C, Ballester P, Crozat K . NF-κB-dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity. Sci Immunol. 2021; 6(61). DOI: 10.1126/sciimmunol.abg3570. View

Pinheiro C, Miranda-Goncalves V, Longatto-Filho A, Vicente A, Berardinelli G, Scapulatempo-Neto C . The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4. Cell Cycle. 2016; 15(11):1462-70. PMC: 4934068. DOI: 10.1080/15384101.2016.1175258. View

Zhang J, Zhou N, Lin A, Luo P, Chen X, Deng H . ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer. Cancer Immunol Immunother. 2020; 70(1):137-151. PMC: 10992006. DOI: 10.1007/s00262-020-02668-8. View

Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

McLaughlin M, Patin E, Pedersen M, Wilkins A, Dillon M, Melcher A . Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020; 20(4):203-217. DOI: 10.1038/s41568-020-0246-1. View

10.

Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen S . Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv. 2018; 1(1):47-61. PMC: 5744057. DOI: 10.1182/bloodadvances.2016000984. View

11.

Abdelsamed H, Zebley C, Youngblood B . Epigenetic Maintenance of Acquired Gene Expression Programs during Memory CD8 T Cell Homeostasis. Front Immunol. 2018; 9:6. PMC: 5778141. DOI: 10.3389/fimmu.2018.00006. View

12.

Atkins M, Lotze M, Dutcher J, Fisher R, Weiss G, Margolin K . High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17(7):2105-16. DOI: 10.1200/JCO.1999.17.7.2105. View

13.

Esensten J, Helou Y, Chopra G, Weiss A, Bluestone J . CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016; 44(5):973-88. PMC: 4932896. DOI: 10.1016/j.immuni.2016.04.020. View

14.

Zheng W, Skowron K, Namm J, Burnette B, Fernandez C, Arina A . Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget. 2016; 7(28):43039-43051. PMC: 5190006. DOI: 10.18632/oncotarget.9915. View

15.

Waldmann T, Dubois S, Miljkovic M, Conlon K . IL-15 in the Combination Immunotherapy of Cancer. Front Immunol. 2020; 11:868. PMC: 7248178. DOI: 10.3389/fimmu.2020.00868. View

16.

Hegde P, Karanikas V, Evers S . The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clin Cancer Res. 2016; 22(8):1865-74. DOI: 10.1158/1078-0432.CCR-15-1507. View

17.

Nagarsheth N, Peng D, Kryczek I, Wu K, Li W, Zhao E . PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. Cancer Res. 2015; 76(2):275-82. PMC: 4715964. DOI: 10.1158/0008-5472.CAN-15-1938. View

18.

Moore E, Clavijo P, Davis R, Cash H, Van Waes C, Kim Y . Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. Cancer Immunol Res. 2016; 4(12):1061-1071. PMC: 5134907. DOI: 10.1158/2326-6066.CIR-16-0104. View

19.

Rosenberg S, Yang J, Restifo N . Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10(9):909-15. PMC: 1435696. DOI: 10.1038/nm1100. View

20.

Agliardi G, Liuzzi A, Hotblack A, De Feo D, Nunez N, Stowe C . Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021; 12(1):444. PMC: 7815781. DOI: 10.1038/s41467-020-20599-x. View